Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

159.14 +1.05 (+0.66%)
Official Closing Price Updated: 7:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,142,969
Open 158.56
Bid (Size) 158.65 (1)
Ask (Size) 159.70 (1)
Prev. Close 158.09
Today's Range 158.05 - 159.74
52wk Range 95.02 - 159.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Stocks That Could Benefit From the Ozempic Craze
Is it time to load up on these weight-loss stocks? 
Via The Motley Fool
BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion
BioRestorative Therapies Inc (NASDAQ: BRTX) is expanding its ThermoStem® intellectual property portfolio for treatments targeting obesity, diabetes and other indications related to metabolic syndrome... 
Via Benzinga

Performance

YTD
+16.19%
+16.19%
1 Month
+10.82%
+10.82%
3 Month
+16.19%
+16.19%
6 Month
+55.18%
+55.18%
1 Year
+40.94%
+40.94%

More News

Read More
Novo Nordisk's Obesity Drug May Find Place On World Health Organization's 'Essential Medicines List'
Via Benzinga
The Government Move That Could Drive Obesity Drugs — And Lilly, Novo Shares
Via Investor's Business Daily
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
Via The Motley Fool
Looking Into Novo Nordisk's Recent Short Interest
Via Benzinga
Novo Nordisk Suspended From UK Trade Association For Practice Breaches
Via Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 5 Years
Via Benzinga
Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%?
Via The Motley Fool
Viking Therapeutics' Initial VK2735 'Data Resoundingly Beat Expectations,' Analyst Says
Via Benzinga
Is Viking Therapeutics a Smart Buy on the Dip?
Via The Motley Fool
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
Via Investor's Business Daily
Novo Nordisk's Higher Dose Oral Semaglutide Shows Superior Reductions In Sugar Levels, Body Weight
Via Benzinga
Chart Of The Day: Novo Nordisk - All Time High
Via Talk Markets
2 Top Healthcare Stocks to Buy for the Long Haul
Via The Motley Fool
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%
Via Benzinga
Novo Nordisk Follows Eli Lilly In Slashing Insulin Prices By 75%
Via Benzinga
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
Via Benzinga
Jimmy Kimmel Jokes At Oscars About Hollywood Stars Using This Diabetes Drug To Lose Weight — Roasts Will Smith Slap Too
Via Benzinga
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Via TheNewswire.com
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Via News Direct
BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Via Benzinga
Looking To Shed Some Pounds? WeightWatchers To Offer Weight-Loss Drugs Like Ozempic
Via Benzinga
WW Stock Soars As Telehealth Deal Opens Up Hot Obesity Drug Market
Via Investor's Business Daily
AI Stock Headlines 5 Leaders Flashing Buy Signals As Market Rally Gains Steam
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.